Caption Health gets FDA nod for echo AI software

The U.S. Food and Drug Administration (FDA) said it has cleared artificial...Read more on AuntMinnie.comRelated Reading: Bay Labs changes name, gets FDA designation Bay Labs touts AI research at ASE 2019 AI firm Bay Labs touts upcoming ACC 2019 studies Bay Labs, Edwards collaborate on AI for heart imaging Bay Labs: AI software less variable than doctors for EF
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

No abstract available
Source: ASAIO Journal - Category: Medical Devices Tags: Letters to the Editor Source Type: research
Continuous-flow left ventricular assist devices (CF-LVADs) are increasingly used in advanced heart failure patients. Recent studies suggest that low socioeconomic status (SES) predicts worst survival after heart transplantation. Both individual-level and neighborhood-level SES (nSES) have been linked to cardiovascular health; however, the impact of SES in CF-LVAD patients remains unknown. We hypothesized that SES is a major determinant of CF-LVAD candidacy and postimplantation outcomes. A retrospective chart review was conducted on 362 patients between February 2009 and May 2016. Neighborhood-level SES was measured using t...
Source: ASAIO Journal - Category: Medical Devices Tags: Adult Circulatory Support Source Type: research
No abstract available
Source: ASAIO Journal - Category: Medical Devices Tags: Invited Commentary Source Type: research
Left ventricular assist devices (LVADs) have dramatically improved short-term outcomes among patients with advanced heart failure. While neurohormonal blockade (NHB) is the cornerstone of treatment for patients with heart failure with reduced ejection fraction, its effect after LVAD placement has not been established. We reviewed medical records of 307 patients who underwent primary LVAD implantation from January 2006 to September 2015 at two institutions in the United States. Patients were followed for at least 2 years post-LVAD implantation or until explantation, heart transplantation, or death. Cox regression analysis s...
Source: ASAIO Journal - Category: Medical Devices Tags: Adult Circulatory Support Source Type: research
Artificial neural network (ANN) and its variants are favored algorithm in designing cardiac arrhythmia classifier (CAC) for its high accuracy. However, the implementation of ultralow power ANN-CAC is challenging due to the intensive computations. Moreover, the imbalanced MIT-BIH database limits the ANN-CAC performance. Several novel techniques are proposed to address the challenges in the low power implementation. Firstly, continuous-in-time discrete-in-amplitude (CTDA) signal flow is adopted to reduce the multiplication operations. Secondly, conditional grouping scheme (CGS) in combination with biased training (BT) is pro...
Source: IEEE Transactions on Biomedical Circuits and Systems - Category: Biomedical Engineering Source Type: research
This study, for the first time, shows that transplantation of non-autologous mitochondria from healthy skeletal muscle cells into normal cardiomyocytes leads to short-term improvement of bioenergetics indicating "supercharged" state. However, over time these improved effects disappear, which suggests transplantation of mitochondria may have a potential application in settings where there is an acute stress. Outlining Some of the Science Behind Partial Reprogramming at Turn.bio https://www.fightaging.org/archives/2020/03/outlining-some-of-the-science-behind-partial-reprogramming-at-turn-bio/ Tur...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Primary graft dysfunction (PGD), defined as the presence of lung allograft infiltrates consistent with pulmonary edema and hypoxemia, is a devastating early complication of lung transplantation (1). PGD is a major risk factor for poor outcomes after lung transplant including death and development of chronic lung allograft dysfunction (CLAD) (2-4). Numerous studies have defined clinical risk factors for PGD (4) and there is extensive literature studying mechanisms of ischemia-reperfusion injury in experimental model systems (5).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
The recent publication by Davila et al evaluated the impact of donor left ventricular ejection fraction (LVEF) on the association between risk factors of 1-year mortality post heart transplantation and post-transplant outcomes. 1 The authors developed multivariable cox regression models including variables related to donor and recipient characteristics, stratified their models by the donor LVEF groups, and compared the observed associations from each strata. By doing so, the authors concluded that in subgroups of recipients transplanted with reduced LVEF donors, the association between ischemic time and 1-year mortality is stronger.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
Obesity characterized by a body mass index (BMI)> 35 kg/m2 is associated with increased morbidity and mortality after orthotopic heart transplantation (OHT)1. This degree of obesity (classified as Class 2 or higher) results in longer wait times and reduced likelihood of matching a suitable organ donor.2 Consequently, the International Society for Heart and Lung Transplantation guidelines for listing candidates for OHT recommend a goal BMI of less than 35 kg/m2, and suggest that durable left ventricular assist device (LVAD) may be used as a bridge to candidacy with goal directed weight loss.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Cardiology | Food and Drug Administration (FDA) | Heart | Heart Transplant | Radiology | Study